A ten-year surveillance for antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae in community- and hospital-associated intra-abdominal infections in China.
J Med Microbiol. 2013 Jun 5;
Authors: Yang Q, Zhang H, Wang Y, Xu Y, Chen M, Badal RE, Wang H, Ni Y, Yu Y, Hu B, Sun Z, Huang W, Wang Y, Wu A, Feng X, Liao K, Shen D, Hu Z, Chu Y, Lu J, Cao B, Su J, Gui B, Duan Q, Zhang S, Shao H, Kong H, Hu Y, Ye H
The objective of this study was to investigate the susceptibility of hospital- and community-associated Escherichia coli and Klebsiella pneumoniae isolated from patients with intra-abdominal infections in China. From 2002 to 2011, the minimum inhibitory concentrations (MICs) of 12 antibiotics against 3,074 E. coli and 1,025 K. pneumoniae from 23 centers located in 16 cities were determined by the broth microdilution method. During the ten-year study period, ertapenem, imipenem, amikacin and piperacillin-tazobactam retained high and stable activity against E .coli and K. pneumoniae isolates regardless of their source (hospital-associated [HA] or community-associated [CA]) and extended-spectrum beta-lactamase (ESBL) production. However, the susceptibility of E. coli to cephalosporins and ampicillin-sulbactam decreased dramatically during the ten years, especially for the CA isolates. Fluoroquinolones showed low activity against E. coli. During the whole study period, the ESBL rates for E. coli isolates from IAIs increased from 36.1% in 2002-2003 to 68.1% in 2010-2011 (P<0.001). Correspondingly, the ESBL rates in HA isolates increased from 52.2% in 2002-2003 to70.0% in 2010-2011 (P=0.001), and in CA isolates from 19.1% in 2002-2003 to 61.6% in 2010-2011 (P<0.001). The ESBL-positive rate in K. pneumoniae remained between 30.1-39.3% of the total isolates with no significant change during the ten years. In conclusion, carbapenems retained the highest susceptibility rates against HA and CA E. coli and K. pneumoniae. High prevalence of ESBL in HA E. coli and fast-growing resistance in CA E. coli severely limit the empirical use of the third- and fourth-generation cephalosporins in the therapy of intra-abdominal infections.
PMID: 23741022 [PubMed - as supplied by publisher]